NCT02946190View on ClinicalTrials.gov

The PertADO Geneva Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 27, 2016

Primary Completion Date

March 9, 2017

Study Completion Date

March 9, 2017

Conditions
Pertussis
Interventions
BIOLOGICAL

Pertagen® aP + Td-pur®

see arm/group descriptions

BIOLOGICAL

Boostrix® dTpa

see arm/group descriptions

Trial Locations (1)

1205

Pediatric clinical trial platform, University Hospitals of Geneva City: Geneva, Geneva

All Listed Sponsors
collaborator

BioNet-Asia Co., Ltd.

INDUSTRY

lead

Siegrist Claire-Anne

OTHER

NCT02946190 - The PertADO Geneva Trial | Biotech Hunter | Biotech Hunter